Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.84)
# 76
Out of 5,154 analysts
44
Total ratings
66.67%
Success rate
62.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Reiterates: Buy | $25 | $7.47 | +234.67% | 3 | Mar 9, 2026 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $58 | $43.03 | +34.79% | 3 | Mar 3, 2026 | |
| CGON CG Oncology | Maintains: Buy | $75 → $80 | $59.96 | +33.42% | 5 | Feb 27, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $25 → $22 | $21.29 | +3.36% | 2 | Feb 25, 2026 | |
| IBRX ImmunityBio | Maintains: Buy | $10 → $15 | $8.34 | +79.86% | 9 | Feb 23, 2026 | |
| IMNM Immunome | Initiates: Buy | $40 | $20.30 | +97.09% | 1 | Feb 12, 2026 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $5.53 | +316.29% | 3 | Feb 10, 2026 | |
| NBP NovaBridge Biosciences | Maintains: Buy | $7 → $9 | $3.37 | +167.06% | 1 | Feb 6, 2026 | |
| VSTM Verastem | Assumes: Buy | $18 | $6.30 | +185.71% | 1 | Feb 4, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $15 | $15.28 | -1.83% | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $10 | $23.92 | -58.19% | 1 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.69 | +483.77% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $60 | $42.04 | +42.72% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.20 | +483.33% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $23.62 | +69.35% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $8.94 | +347.43% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.00 | +360.00% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $55.97 | +87.60% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $5.49 | +300.73% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $11.20 | +78.57% | 1 | Aug 8, 2025 |
enGene Holdings
Mar 9, 2026
Reiterates: Buy
Price Target: $25
Current: $7.47
Upside: +234.67%
Scholar Rock Holding
Mar 3, 2026
Reiterates: Buy
Price Target: $58
Current: $43.03
Upside: +34.79%
CG Oncology
Feb 27, 2026
Maintains: Buy
Price Target: $75 → $80
Current: $59.96
Upside: +33.42%
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $21.29
Upside: +3.36%
ImmunityBio
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $8.34
Upside: +79.86%
Immunome
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $20.30
Upside: +97.09%
Protara Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.53
Upside: +316.29%
NovaBridge Biosciences
Feb 6, 2026
Maintains: Buy
Price Target: $7 → $9
Current: $3.37
Upside: +167.06%
Verastem
Feb 4, 2026
Assumes: Buy
Price Target: $18
Current: $6.30
Upside: +185.71%
Erasca
Jan 26, 2026
Maintains: Buy
Price Target: $11 → $15
Current: $15.28
Upside: -1.83%
Dec 22, 2025
Maintains: Neutral
Price Target: $2 → $10
Current: $23.92
Upside: -58.19%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.69
Upside: +483.77%
Dec 9, 2025
Maintains: Buy
Price Target: $20 → $60
Current: $42.04
Upside: +42.72%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.20
Upside: +483.33%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $23.62
Upside: +69.35%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $8.94
Upside: +347.43%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $5.00
Upside: +360.00%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $55.97
Upside: +87.60%
Aug 13, 2025
Reiterates: Buy
Price Target: $22
Current: $5.49
Upside: +300.73%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $11.20
Upside: +78.57%